We are a development stage, NIH-supported company developing the first biologic for the treatment of dry eye, called Protearin. Protearin is a recombinantly expressed form of the natural tear glycoprotein clusterin. Unlike the two FDA-approved drugs currently available, Protearin targets ocular surface damage, the final common endpoint of all dry eye forms, via a novel combination of sealing and healing properties. It should be uniquely effective